Stefan Wawersik

Stefan Wawersik is a seasoned professional in the biotechnology field, currently serving as the VP of Biology at Ampersand Biomedicines since September 2024. Previously, Stefan held key positions at Q32 Bio Inc., where responsibilities included serving as Vice President & Head of Research and Translational and Senior Director of Preclinical Research from December 2020 to September 2024. At Scholar Rock, from July 2015 to December 2020, Stefan advanced from Senior Scientist to Director of Preclinical Sciences, focusing on bioanalytical and translational technologies. Stefan's earlier career at Sanofi Genzyme involved roles as Senior Scientist and Staff Scientist, specializing in pharmacology and model development for rare kidney diseases. Beginning as a Postdoctoral Fellow at Harvard Medical School from April 2000 to May 2004, Stefan's research concentrated on TGFb/BMP signaling in neural development. Stefan Wawersik holds a PhD in Genetics from Harvard University and a BA in Biochemistry from Rice University.